Table 1.
Baseline characteristics of CMML patients treated with ruxolitinib
| Baseline characteristic | (n = 20) |
|---|---|
| Median age (range) | 69 (48–84) |
| Male (%) | 15 (75%) |
| WHO classification | |
| CMML-1 (%) | 20 (100%) |
| CMML-2 (%) | 0 (0%) |
| FAB classification | |
| MDS-CMML (%) | 6 (30%) |
| MPN-CMML (%) | 14 (70%) |
| Risk stratification (MDASC) | |
| Lower risk (%) | 70% (14) |
| Higher risk (%) | 30% (6) |
| Hypomethylating agent status | |
| Treatment (%) | 40% (8) |
| No treatment (%) | 60% (12) |
| Splenomegaly (%) | 9 (45%) |
| Median WBC × 103/dL (range) | 22 (2.3–92.9) |
| Median AMC × 103/dL (range) | 2.93 (0.61–5.83) |
| Median HGB g/dL | 10.4 (6.3–14.2) |
| Median PLT × 103/dL | 152 (41–488) |
| Disease-related/constitutional symptomsa | 11 (55%) |
Abbreviations: AMC, absolute monocyte count; HGB, hemoglobin; MDASC, Global MD Anderson Scoring System; PLT, platelets; WBC, white blood cell count.
a
As reported by medical record abstraction.